Who are Insulin/Empaglifozin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Insulin/Dapaglifozin, Insulin/Canaglifozin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/insulin-empaglifozin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Insulin/Empaglifozin — Competitive Intelligence Brief

Insulin/Empaglifozin (Insulin/Empaglifozin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin + SGLT2 inhibitor combination. Area: Diabetes.

marketed Insulin + SGLT2 inhibitor combination Insulin receptor; SGLT2 (sodium-glucose cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin/Empaglifozin (Insulin/Empaglifozin) — University of Campania Luigi Vanvitelli. This combination uses insulin to lower blood glucose while empaglifozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Insulin/Empaglifozin TARGET	Insulin/Empaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)
Insulin/Dapaglifozin	Insulin/Dapaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)
Insulin/Canaglifozin	Insulin/Canaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin + SGLT2 inhibitor combination class)

University of Campania Luigi Vanvitelli · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin/Empaglifozin — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-empaglifozin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab